Thanks for the info LPP! While the $120K price
Post# of 148169
While the $120K price tag may seem high especially since the price just a couple months ago was only $24K, it may be in-line with current cancer and HIV Resistance treatments (IZ). The price increases have occurred after discussing with BPs for potential license deals and likely insurance companies also. If insurance is agreeing to this price then it may be an accurate for at least for initial launch. This may also be a conversation in regards to the company potentially treating patients under the Expanded Access Program at cost until FDA approval....which may also be in goodwill discussion with insurance paying a much lower cost between now and FDA approval (all speculation and pending positive clinical cancer results).
However, the bigger takeaway for me about today's news is that the deal increased from $500M to $1B. I know NP previously mentioned the future years being $1B, but I understand that even 2020 amount is $1B. Does anyone understand this differently? If so, this tells me they expect more than $500M sales in 2020 regardless if you use $70K or $120K annual revenue numbers.....especially since they already have $200M in inventory.